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Current pharmacotherapy of anxiety disorders and
depression mainly targets GABAA receptors and monoam-
ines such as the serotonin and noradrenaline systems,
respectively. They are effective, but an improvement of
their therapeutic efficacy in regard of therapeutic onset,
side effects and the number of treatment responders is
desired. Here, we tested the sensitivity of a mouse line
characterised by extremely high levels of trait anxiety and
co-occurring depression (HAB) to the selective neuroki-
nin-1 receptor (NK1R) antagonist [2-cyclopropoxy-5-(5-
(trifluoromethyl)tetrazol-1-yl)benzyl]-(2-phenylpiperi-
din-3-yl)amine using a battery of established tests reveal-
ing anxiety- and depression-related behaviours. Chronic
administration of the NK1R antagonist via the drinking
water increased the time spent in the brightly lit compart-
ment of the light/dark test and attenuated fear responses
in a classical cued fear conditioning paradigm in male and
female HAB animals. In addition, the enhanced immobil-
ity times of HABs displayed in the forced swim and tail
suspension tests were reduced. These findings indicate a
clear anxiolytic and antidepressant effect of chronic NK1R
antagonist treatment in HAB animals which have not
responded to any classical, clinically effective pharmaco-
therapy tested so far including paroxetine or diazepam.
Moreover, they raise the possibility of a hyperactive sub-
stance P/NK1R neurotransmission in the HAB line. To test
this hypothesis, we performed in situ hybridisation stud-
ies in the forebrain of HAB mice, their low anxiety/depres-
sion (LAB) counterparts and unselected CD1 (NAB) mice.
Indeed, the abundance of Tac1 mRNA, the precursor of
substance P was elevated in the habenula and ventrome-
dial hypothalamus of HAB compared to NAB and/or LAB
mice suggesting that up-regulated transcriptional proc-
esses in the substance P system may contribute to the
enhanced anxiety- and depression-related behaviours of
HABs. Chronic NK1R antagonist treatment did not alter
the high Tac1 mRNA expression of HAB mice. In addition,
the HAB vs. the other two lines displayed reduced BDNF
mRNA expression in the dentate gyrus and increased met-
enkephaline mRNA expression in the hippocampal CA3
region which both were not altered following chronic
NK1R antagonist treatment. Taken together, the present
results indicate that the HAB mouse line may represent a
unique, clinically relevant model to study drug targets and
underlying neurochemistry with potential clinical benefit
in treatment-resistant pathological anxiety and co-occur-
ring depression.
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